|
|
 |
|
Viewing report
|
|
|
|
Stakeholder Opinions: Hemophilia - The harsh reality of commercialising a great research opportunity?
Datamonitor, June 2010, Pages: 108
Hemophilia management has a small pipeline of developmental products, focusing on next-generation enhancements of expensive existing treatment approaches, but is likely to face some key challenges in an era of budget deficits and growing costs of care.
Scope of this research:
- Defining the key clinical characteristics of the hemophilia population that present a unique commercial challenge
- Translating critical clinical issues into pertinent practical considerations for incumbent players and new market entrants.
- Clinical and commercial analysis of key marketed drugs and future treatment directions
- Patient potential analysis for hemophilia A and B
Research and analysis highlights
Hemophilia A and B are rare, with an estimated worldwide prevalence of 664,000, of which just 160,000 were reported in 2008. Diagnosis and survival rates vary dramatically across geographies and economies with the US, Japan, France, Germany, Italy, Spain and the UK accounting for just 11% of the predicted prevalence, but 25% of reported prevalence
Life expectancy and quality of life can be dramatically improved with current approaches, but only at an incredible cost: Cost per quality adjusted life year estimates for factor replacement in children range from $50,000 to $2,700,000, partly because treatment may prompt exceptionally expensive and dangerous side-effects.
Hemophilia gene therapy advances have stalled, leaving the late stage pipeline to focus on protein engineering technologies already exploited in other disease areas. These largely offer dosing improvements, but it is uncertain whether this will result in more universally affordable treatment products sought by the majority of hemophilia sufferers
Key reasons to purchase this research:
- Characterize a high value niche patient group
- Understand the evolution of current management strategies
- Assess current unmet needs and challenges and prospects for next-generation products
Customers who bought this item also bought
Do Emerging Therapies Offer Better Treatment Options for Hemophilia Patients?
Forecast Insight: HIV - Increasing dominance of fixed dose combinations raises bar for single agents
Ankylosing Spondylitis: Surveyed Rheumatologists Await Non-TNF-Alpha Inhibitor Therapies in an Underserved Market
Juvenile Idiopathic Arthritis (JIA): KOL Insights on Treatment Practices and Unmet Needs
Hepatitis C Virus and Therapeutics - Global Strategic Business Report
Will Emerging Agents Disrupt the Psoriatic Arthritis Market?
Nitric Oxide - Therapeutics, Markets and Companies
Neuropathic Pain: Treatments and Prescribing Practices - A Global Survey 2009
Radiation Therapy Equipment - Global Strategic Business Report
Disease and Therapy Review: Myocardial Infarction
|
|
|
|
